Financing channel feed – Endpoints News

Financing channel feed

Hunting for early-stage life sciences bets, Partners Healthcare closes $171M for venture fund

8 years ago

Prepping PhIII for Soliris rival, Apellis rides a boisterous market to a $150M IPO

8 years ago

Eyeing Duchenne MD cure, The Column Group gambles $40M on CRISPR/Cas9 startup Exonics

8 years ago

German biotech InflaRx raises $100M in IPO

8 years ago

Amgen bets on stem cell company Fortuna Fix in $25M round

8 years ago

Upstart Oyster Point has big plans for disrupting the ophthalmology space, but you'll have to wait for the details

8 years ago

Boasting in-license distribution model, Chinese EOC Pharma bags $32M series B funding for oncology products

8 years ago

Bill Gates and rich allies help fund an alt-biotech startup path for the gene expression experts at Exicure

8 years ago

Two years in, the team at NousCom bags $49M to fund first human studies of neoantigen drugs

8 years ago

IPO market warms with Spero, Allena heading to Wall Street

8 years ago

Shkreli out, Cuban in: Twitter proves essential for biotech rebel Ethan Perlstein

8 years ago

Frazier boosts next pure-play biotech fund to $419M, readies new bets for a practiced strategy

8 years ago

Bristol-Myers, J&J sink cash into a new $95M European biotech fund

8 years ago

Grail CSO Vikram Bajaj jumps to VC firm Foresite, takes lead on personalized meds

8 years ago

Atlas-incubated Kymera leaps out of stealth mode, joins the hunt for game-changing protein degradation drugs

8 years ago

John Hood bags $90M for his quest to get fedratinib OK’d by FDA and catapult into the market

8 years ago

Ablynx IPO raises $200M for its nanobody platform effort

8 years ago

Eyeing a big heart failure market, scPharmaceuticals aims for $100M IPO

8 years ago

Genmab vets at low-profile Y-mAbs steer two MSK cancer drugs to the FDA after landing $50M from HBM

8 years ago

Going all in: Biogen commits an extra $500M to Alzheimer’s blockbuster hopeful aducanumab

8 years ago

With a pipeline from Gerngross’ Adimab, Arsanis hunts a $58M IPO for antibody development work

8 years ago

Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca

8 years ago

Peer Review: Eyeing a $350M venture fund, Nextech recruits Third Rock’s Jakob Loven for the team

8 years ago

Google’s GV and allies double down on Forty Seven with their second $75M round

8 years ago

First page Previous page 134 135 136137138 139 140 Next page Last page